{"entity":{"id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","aka":[],"tldr":"A phase 1/2 trial of WJ22096 in advanced solid tumours, run by Nanjing Jingao biomidical technology Co. Ltd., now recruiting.","summary":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT07253116 by Nanjing Jingao biomidical technology Co. Ltd., with 20 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-11-30. Interventions recorded: WJ22096.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07253116","url":"https://clinicaltrials.gov/study/NCT07253116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07253116","phase":"1/2","setting":"A Phase I/II, Dose-Escalation, Dose-Expansion, and Efficacy-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJ22096 Tablets Administered Orally in Patients With Advanced Solid Tumors","sponsor":"Nanjing Jingao biomidical technology Co. Ltd.","enrolled":20,"outcomes":[]},"route":"/trials/nct07253116/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}